Some lots of Pfizer’s leading smoking cessation treatment, Champix, will be voluntarily recalled.

Although the drugs were not subject to recall under the MFDS announcement on the 7th, Pfizer opted to voluntarily recall its products as the drugs exceeded the MFDS's temporary release standards. The standards that the company applied for recall were stricter than the initial recall standards set by the Ministry of Food and Drug Safety that had raised controversy over how the initial standards were set.

On the 17, the MFDS announced that 9 lots of Pfizer Korea's ‘Champix 1mg (varenicline tartrate)’ will be voluntarily recalled by its seller.

The lot numbers of the